Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sherene Loi

Showing results (151-160 of 325) with videos related to

Pageof 33
Sort By:
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
Breast (Edinburgh, Scotland)|December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Future Oncology (London, England)|November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancerSara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast CancerKomal L Jhaveri, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2019
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast CancerNicholas C Turner, Yuan Liu, Zhou Zhu, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Pageof 33

Showing results (151-160 of 325) with videos related to

Sort By:
Pageof 33
The Oncologist|January 24, 2021
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-UpRichard S Finn, Hope S Rugo, Karen A Gelmon, et al.
The Lancet. Oncology|December 2, 2019
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trialPeter Schmid, Hope S Rugo, Sylvia Adams, et al.
Breast (Edinburgh, Scotland)|December 4, 2022
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3Hope S Rugo, Seock-Ah Im, Anil A Joy, et al.
Journal of the National Cancer Institute|July 23, 2018
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast CancerVéronique Diéras, Hope S Rugo, Patrick Schnell, et al.
Future Oncology (London, England)|November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancerSara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Dissecting the heterogeneity of triple-negative breast cancerOtto Metzger-Filho, Andrew Tutt, Evandro de Azambuja, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Inavolisib in <i>PIK3CA</i>-Mutated Advanced Breast CancerKomal L Jhaveri, Seock-Ah Im, Cristina Saura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2019
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast CancerNicholas C Turner, Yuan Liu, Zhou Zhu, et al.
Journal of the National Cancer Institute|February 1, 2021
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 StudyLeisha A Emens, Luciana Molinero, Sherene Loi, et al.
Pageof 33